Cereno's PAH investigational candidate CS1 granted compassionate use
The FDA has approved the use of Cereno Scientific’s CS1 in an extension of the ongoing Phase 2 trial testing the therapy in people with PAH.| Pulmonary Hypertension News
The FDA has approved the use of Cereno Scientific’s CS1 in an extension of the ongoing Phase 2 trial testing the therapy in people with PAH.| Pulmonary Hypertension News
Cereno Scientific reported a successful meeting with the FDA on the design of a future clinical trial for its PAH therapy candidate CS1.| Pulmonary Hypertension News
